Skip to content
Home » FDA Approval For A Study of Brain Implants In Humans Says Elon Musk’s Neuralink

FDA Approval For A Study of Brain Implants In Humans Says Elon Musk’s Neuralink

Neuralink Elon Musk's

Green light is given to Neuralink Elon Musk’s brain-implant company by the U.S. Food and Drug Administration (FDA) on Thursday. Neuralink is the first-in-human clinical trial that has created a milestone after many struggles to gain approval. 

Neuralink said in a tweet that the FDA nodded to the representation of an important first step that one day will allow the technology to help many people. The company does not intend to recruit yet but more details will be available in the coming days

A wide range of conditions such as schizophrenia, obesity, autism, and depression along with web telepathy and browsing will be enabled. Musk was on top of the headline last year as he claimed he would be able to implant the devices in the children which is about a few steps away now.

Musk made a prediction in 2019 that Neuralink would begin human trials but the company received its approval only in 2022 from FDA and the agencies also rejected the application told Reuters.

According to the employees FDA has pointed out to Neuralink that it needs to address this before it sanctions human trials. One of the major challenges and issues is the device’s battery, the possibility of the implant’s wires migrating within the brain, and the challenge of safely extracting the device without damaging brain tissue.

The U.S. lawmakers in May, asked for regular investigation at Neuralink of a panel to oversee animal testing that is contributed to botched and rushed experiments.

The U.S. Department of Agriculture’s Office of Inspector General has also been investigating Neuralink for potential animal-welfare violations as there was a claim which said there had been illegal and dangerous pathogens on chips has been in transportation removed from monkey brains without proper containment measures.

Leave a Reply

Your email address will not be published. Required fields are marked *